Toxicological implications of polymorphic drug metabolism

Area of Science:

• Pharmacogenomics
• Metabolic pathways

Background:

• Genetic polymorphisms lead to distinct metabolic phenotypes.
• These phenotypes significantly influence individual responses to drugs and toxins.
• Established polymorphisms in acetylation and hydrolysis highlight phenotype-drug response associations.

Purpose of the Study:

• To describe a newly identified genetic polymorphism in metabolic oxidation.
• To elucidate its role in inter-individual variability of drug metabolism and response.
• To understand its impact on drug availability, toxicity, and adverse effects.

Main Methods:

• Review of recent findings on metabolic oxidation polymorphisms.
• Analysis of polymorphism's influence on presystemic metabolism.
• Examination of its role in alternative metabolic pathways and toxic responses.
• Investigation of its contribution to drug-induced agranulocytosis.

Main Results:

• The oxidation polymorphism affects presystemic drug metabolism and systemic availability.
• It influences the activation of alternative, potentially toxic metabolic pathways.
• The polymorphism is implicated in the development of metiamide-induced agranulocytosis.

Conclusions:

• The newly described oxidation polymorphism is crucial for understanding drug metabolism variability.
• It impacts drug efficacy, toxicity, and adverse event profiles.
• This finding enhances our comprehension of pharmacogenetic influences on drug response.